TCPG
TVTX icon

Trivant Custom Portfolio Group’s Travere Therapeutics TVTX Stock Holding History

Trivant Custom Portfolio Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$1.79K – 202
2025
Q1 		$1.79K Buy
+100
New +$2.03K ﹤0.01% 182
2023
Q4 		– Sell
-575
Closed -$5.14K – 217
2023
Q3 		$5.14K Hold
575
– – ﹤0.01% 179
2023
Q2 		$8.83K Hold
575
– – 0.01% 175
2023
Q1 		$12.9K Buy
+575
New +$12.2K 0.01% 173

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trivant Custom Portfolio Group's TVTX Position: Q2 2025 in Review

Trivant Custom Portfolio Group sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 100 shares — an estimated $1.79K sold.

Trivant Custom Portfolio Group first reported a position in TVTX in Q1 2023 and held it in 4 quarters. The position peaked at $12.9K in Q1 2023. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Trivant Custom Portfolio Group reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 100 Travere Therapeutics shares in Q2 2025, an estimated $1.79K.
  • Trivant Custom Portfolio Group first reported a position in Travere Therapeutics in Q1 2023 and held it in 4 quarters.
  • Trivant Custom Portfolio Group's Travere Therapeutics position peaked at $12.9K in Q1 2023.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2025, filed 12 Aug 2025.